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1. Introduction 2. Materials and methods 
Cl-inhibitor, a plasma protein with a very high 
amount of carbohydrates (34% by wt, 17% of which 
is sialic acid) is composed of a single polypeptide chain 
o fM r 105 000 [1-4].  It inhibits a variety of enzymes 
of the complement system as well as others (e.g., plas- 
min, kallikrein, Hageman factor). The exact nature of 
the reaction of this inhibitor with the enzymes is un- 
clear. With activated Cis, its most likely in vivo sub- 
strate, a 1:1 complex is formed which remains table 
even in SDS and urea. 
It has been shown that Cl-inhibitor is a lysyl-type 
inactivator [5]. Evidence has been provided that C1- 
inhibitor contains terminal sialic acid residues and 
penultimate galactose residues [6]. In vivo infused 
asialo-Cl-inhibitor is rapidly cleared from the serum 
of rabbits while asialo-agalactose-Cl-inhibitor remains 
uncleared for about the same time as the native mol- 
ecule, indicating that exposure of galactosyl residues 
might render the molecule recognizable by receptors. 
Interestingly, removal of the carbohydrate moiety does 
not alter the inhibitory activity of the molecule [6]. 
Concerning the structure, only hydrodynamic data 
are available so far. The extremely small sedimenta- 
tion coefficient of 3.7 S [3] for a molecule of this 
size indicates avery elongated structure. Our electron 
micrographs provide for the first time more detailed 
information on the structure of this interesting mol- 
ecule. 
Abbreviations: SDS PAGE, polyacrylamide g l electropho- 
resis in the presence of sodium dodecyl sulfate; Mr, relative 
molecular mass 
Nomenclature: The complement terminology used conforms 
to the recommendations of the World Health Organisation 
Committee on Complement Nomenclature (Bull. WHO 
(1968) 39, 935-938) 
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Fresh human plasma was obtained from the Blut- 
spendezentrum, Basel. Cl-inhibitor was prepared 
according to [7]. Further purification was achieved 
on a hydroxylapatite column. The protein was homo- 
geneous as judged by SDS-PAGE and by analytical 
ultracentrifugation (Beckman model E, equipped 
with a photoelectric scanner), with a sedimentation 
coefficient of 3.7 S in agreement with [3]. The activ- 
ity of the inhibitor was determined by the formation 
of a complex with activated s  (SDS-PAGE) and by 
its ability to inhibit the esterase activity of ds  using 
p-tosyl-L-arginine methyl ester as a substrate. 
Sample preparation for the electron microscope 
was done essentially as in [8]. The rotatory shadowing 
technique as well as the negative staining method was 
employed. 
DEAE-Sephacel and con A-Sepharose were pur- 
chased from Pharmacia, hydroxylapatite from Bio- 
Rad Labs; a-methyl-D-mannoside and p-tosyl-L-argi- 
nine methyl ester were products of Sigma. 
3. Results 
Fig. 1 (a-e) presents typical electron micrographs 
of the Cl-inhibitor obtained by the rotatory shadow- 
ing technique. It is a very elongated structure. Clearly 
a head and a tail can be distinguished. The length dis- 
tribution of 100 molecules is shown in fig.2. About 
43% of the molecules fall into the range between 33 
and 36 nm. The diameters of the head and the tail 
cannot be accurately determined from these pictures 
[8]. Negatively stained samples (fig.1 f) do not exhibit 
the high contrast of  rotatory shadowed specimen; 
however, their diameters are more precisely repre- 
sented. We estimate them to be ~4 nm for the head 
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and 2 nm for the tail. 
Fig.3 compares a simplified picture of the mole- 
cule as derived from electron microscopy with a 
hydrodynamically equivalent rotational cylinder. The 
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Fig.3. Upper part: Model of Cl-inhibitor constructed with the 
length derived from rotatory shadowing micrographs. The 
diameter of the head and of the tail were taken from nega- 
tively stained molecules. Lower part: Hydrodynamically 
equivalent model of the Cl-inhibitor (M r 105 000, s = 3.7 S, 
= 0.67 cm~/g) assuming a rod-like shape with a diameter of 
2 nm. The bar corresponds to l0 nm. 
hydrodynamic model was calculated according to [9] 
and applying the Svedberg equation under the assump- 
tion that the diameter of the cylinder is 2 nm. 
Fig.1. Electron micrographs ofhuman Cl-inhibitor obtained 
by the rotatory shadowing technique (a-e). Fig.l f shows a 
typical negatively stained molecule. The bar corresponds to
50 nm. 
0.5 
0.25 
No 
18 2t~ 30 36 42 
LENGTH [nm] 
Fig.2. Length distribution of rotatory shadowed human C1- 
inhibitor; 100 molecules were measured. The length was 
determined between the end of the tail and the center of the 
head domain. N/N o denotes the fraction of molecules which 
fall in a range of 3 nm. 
4. Discussion 
Electron micrographs of human Cl-inhibitor reveal 
a highly elongated molecule consisting of a globular 
and a rod-like domain. Rotatory shadowing allows 
determination f the length of the molecule while 
the diameter of the two domains can be estimated 
from negatively stained pictures. A simplified model 
presented in fig.3 consists of a globular structi~re 
having a diameter of 4 nm and a rod-like domain of 
length 33 nm and diameter 2 nm. Assuming a diam- 
eter of 2 nm a hydrodynamically equivalent cylinder 
was calculated according to [9] and the Svedberg 
equation usingM r 105 000, a degree of hydration of 
0.5, a diameter of 2 nm and a partial specific volume 
of 0.67 cm3/g [3]. It confirms qualitatively the result 
of the electron microscopy that Cl-inhibitor is a very 
elongated structure. The quantitative difference in 
length can be attributed to the influence of the head 
as well as to protrusions of tile tail not visible in the 
electron microscope. Side chains of the amino acid 
residues, especially lysine, as well as the carbohydrate 
chains can easily double the diameter observed by 
negative staining. A non-circular cross-section of the 
tail would also increase the frictional coefficient and 
result in a shorter model. 
It is likely that it consists of more than one strand 
because we could resolve the tail by electron micro- 
scopy. Myosin, a coiled coil structure, has a mass/length 
ratio of ~1400 [10]. Applying this ratio to the inhib- 
itor, this gives 1400 X 33 nm _~ 46 000. The remain- 
ing mass can be distributed in a globular head of 
diameter 4.8-5.5 nm depending on the degree of 
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hydration. This indicates that a structure similar to 
that of myosin might be present in the tail. 
The pictures clearly show two domains. Since evo- 
lutionary principles would be eliminated omains 
that are not involved in the inhibition of C[s, there 
might be more than one function for the molecule. 
This and the important question, which domain bears 
the inhibitory site, remain open. 
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